Communiqué de presse
Vertex and CRISPR Therapeutics Announce EMA Marketing Authorization Application Validation for CRISPR/Cas9 Gene-Edited Therapy, exagamglogene autotemcel (exa-cel)
– Application is supported by results from two global Phase 3 studies of exa-cel in people with sickle cell disease […]
